Previous Close | 39.23 |
1-Year Change | 96.15% |
6-Months Change | 18.54% |
3-Months Change | 13.84% |
Moving Avg (50d) | 38.403 |
Moving Avg (200d) | 33.21 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.96B |
Beta (3-Years) | 1.01 |
Revenue Growth (ttm) | 14.58% |
Net Profit Margin (ttm) | -80.4% |
Return On Assets (ttm) | -50.93% |
EPS (ttm) | -8.66 |
PE Ratio (ttm) | -4.53 |
Dividend Yield | % |
Asset Description: | PTC Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-20 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
41.121 | 39.862 | 39.023 | 37.764 | 35.666 | 33.568 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. In 2020,... Wikipedia